One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near? [electronic resource]
Producer: 20070928Description: 1563-8 p. digitalISSN:- 0145-2126
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Chromosomes, Human, Pair 14 -- genetics
- Chromosomes, Human, Pair 18 -- genetics
- Combined Modality Therapy
- Cyclophosphamide -- therapeutic use
- Doxorubicin -- therapeutic use
- Female
- Genes, bcl-2 -- genetics
- Humans
- Immunoglobulin Heavy Chains -- genetics
- Infusions, Intravenous
- Lymphoma, Follicular -- drug therapy
- Male
- Middle Aged
- Prednisone -- therapeutic use
- Remission Induction
- Reverse Transcriptase Polymerase Chain Reaction -- methods
- Rituximab
- Sensitivity and Specificity
- Treatment Outcome
- Vincristine -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.